Conclusions Oral TRT produces significant CV risk .
Differences in the degree to which serum DHT is elevated may underlie the varying CV risk by TRT administration route , as elevated serum dihydrotestosterone has been shown to be associated with CV risk in observational studies
Background Potential cardiovascular ( CV ) risks of testosterone replacement therapy ( TRT ) are currently a topic of intense interest .
However , no studies have addressed CV risk as a function of the route of administration of TRT .
Strength Training and Testosterone Treatment Have Opposing Effects on Migration Inhibitor Factor Levels in Ageing Men
Background . The beneficial effects of testosterone treatment ( TT ) are debated . Methods . Double-blinded , placebo-controlled study of six months TT ( gel ) in 54 men aged 60–78 with bioavailable testosterone ( BioT ) < 7.3 nmol/L and waist > 94 cm r and omized to TT ( 50–100 mg/day , n = 20 ) , placebo ( n = 18 ) , or strength training ( ST ) ( n = 16 ) for 24 weeks . Moreover , the ST group was r and omized to TT ( n = 7 ) or placebo ( n = 9 ) after 12 weeks . Outcomes . Chemokines ( MIF , MCP-1 , and MIP-1α ) and lean body mass ( LBM ) , total , central , extremity , visceral , and subcutaneous ( SAT ) fat mass established by DXA and MRI . Results . From 0 to 24 weeks , MIF and SAT decreased during ST + placebo versus placebo , whereas BioT and LBM were unchanged . TT decreased fat mass ( total , central , extremity , and SAT ) and increased BioT and LBM versus placebo . MIF levels increased during TT versus ST + placebo . ST + TT decreased fat mass ( total , central , and extremity ) and increased BioT and LBM versus placebo . From 12 to 24 weeks , MCP-1 levels increased during TT versus placebo and MCP-1 levels decreased during ST + placebo versus placebo . Conclusion . ST + placebo was associated with decreased MIF levels suggesting decreased inflammatory activity . TT may be associated with increased inflammatory activity . This trial is registered with Clinical Trials.gov NCT00700024
Conclusions Oral TRT produces significant CV risk .
Differences in the degree to which serum DHT is elevated may underlie the varying CV risk by TRT administration route , as elevated serum dihydrotestosterone has been shown to be associated with CV risk in observational studies
Background Potential cardiovascular ( CV ) risks of testosterone replacement therapy ( TRT ) are currently a topic of intense interest .
However , no studies have addressed CV risk as a function of the route of administration of TRT .